ATE512982T1 - Verfahren und zusammensetzung zum gezielten einbringen in exosome - Google Patents
Verfahren und zusammensetzung zum gezielten einbringen in exosomeInfo
- Publication number
- ATE512982T1 ATE512982T1 AT02767380T AT02767380T ATE512982T1 AT E512982 T1 ATE512982 T1 AT E512982T1 AT 02767380 T AT02767380 T AT 02767380T AT 02767380 T AT02767380 T AT 02767380T AT E512982 T1 ATE512982 T1 AT E512982T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- relates
- membrane vesicles
- well
- exosomes
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000001808 exosome Anatomy 0.000 title 1
- 239000012528 membrane Substances 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102100039648 Lactadherin Human genes 0.000 abstract 1
- 101710191666 Lactadherin Proteins 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31315901P | 2001-08-17 | 2001-08-17 | |
| US34399101P | 2001-12-26 | 2001-12-26 | |
| PCT/EP2002/009108 WO2003016522A2 (en) | 2001-08-17 | 2002-08-14 | Methods and compounds for the targeting of protein to exosomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE512982T1 true ATE512982T1 (de) | 2011-07-15 |
Family
ID=26978714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02767380T ATE512982T1 (de) | 2001-08-17 | 2002-08-14 | Verfahren und zusammensetzung zum gezielten einbringen in exosome |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7704964B2 (de) |
| EP (1) | EP1417229B1 (de) |
| JP (1) | JP4662708B2 (de) |
| CN (1) | CN100590131C (de) |
| AT (1) | ATE512982T1 (de) |
| AU (1) | AU2002331244B2 (de) |
| CA (1) | CA2454756C (de) |
| IL (1) | IL160142A0 (de) |
| WO (1) | WO2003016522A2 (de) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE512982T1 (de) | 2001-08-17 | 2011-07-15 | Exothera L L C | Verfahren und zusammensetzung zum gezielten einbringen in exosome |
| AU2003237870A1 (en) * | 2002-06-07 | 2003-12-22 | The Brigham & Women's Hospital, Inc. | Method and composition for inhibing or slowing blood coagulation |
| WO2004073319A2 (en) * | 2003-02-14 | 2004-08-26 | Anosys, Inc. | Methods and compounds for raising antibodies and for screening antibody repertoires |
| US7771956B2 (en) * | 2003-06-30 | 2010-08-10 | Brigham & Women's Hospital, Inc. | Method for detecting the presence of a phospholipid |
| WO2005037229A2 (en) * | 2003-10-17 | 2005-04-28 | Emory University | Methods and compositions for modulating gamete adhesion |
| CN101203234B (zh) * | 2005-05-13 | 2012-10-10 | 范斯坦医药研究院 | 乳脂小球表皮生长因子-因子ⅷ和脓毒病 |
| CN1322115C (zh) * | 2005-07-06 | 2007-06-20 | 清华大学 | 载有外源配体分子的胞外体及其制备方法与应用 |
| CA3061952C (en) * | 2006-03-09 | 2022-07-19 | Aethlon Medical, Inc. | Extracorporeal removal of microvesicular particles |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| US8455188B2 (en) * | 2007-01-26 | 2013-06-04 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
| CA2697629A1 (en) | 2007-09-24 | 2009-04-02 | The University Of Queensland | Molecular delivery vesicle |
| FR2928926B1 (fr) * | 2008-03-18 | 2015-08-21 | Centre Nat Rech Scient | Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes |
| EP2358912B1 (de) * | 2008-10-30 | 2016-10-12 | Caris Life Sciences Switzerland Holdings GmbH | Verfahren zur untersuchung von rna-mustern |
| WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
| GB2463401B (en) | 2008-11-12 | 2014-01-29 | Caris Life Sciences Luxembourg Holdings S A R L | Characterizing prostate disorders by analysis of microvesicles |
| EP3569254B1 (de) | 2009-04-17 | 2022-07-20 | Oxford University Innovation Limited | Zusammensetzungen zur verabreichung von genetischem material |
| FR2950350B1 (fr) * | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
| WO2011097480A1 (en) | 2010-02-05 | 2011-08-11 | University Of Louisville Research Foundation, Inc. | Exosomal compositions and methods for the treatment of disease |
| WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| WO2012021512A2 (en) | 2010-08-10 | 2012-02-16 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| WO2012135844A2 (en) | 2011-04-01 | 2012-10-04 | Cornell University | Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers |
| ITRM20110403A1 (it) | 2011-07-28 | 2013-01-29 | Ospedale Pediatrico Bambino Gesu | Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori. |
| KR20130032646A (ko) * | 2011-09-23 | 2013-04-02 | 삼성전자주식회사 | 막단백질 및 광발생 단백질이 결합된 융합단백질을 포함하는 재조합 엑소좀을 이용한 엑소좀 수득율을 측정하는 방법 |
| GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
| WO2014168721A2 (en) * | 2013-04-12 | 2014-10-16 | Tufts Medical Center | Methods and systems for designing and/or characterizing soluble lipidated ligand agents |
| AU2014251388B2 (en) | 2013-04-12 | 2017-03-30 | Evox Therapeutics Limited | Therapeutic delivery vesicles |
| US10877033B2 (en) | 2013-06-18 | 2020-12-29 | Oxford University Innovation Limited | Method of detecting the presence or absence of autoantibodies |
| GB201313249D0 (en) * | 2013-07-25 | 2013-09-11 | Isis Innovation | Method |
| EP2862874B1 (de) * | 2013-10-15 | 2018-12-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Herstellung polyklonaler Antikörper mit einer Antigenzusammensetzung mit proteinhaltigen Membranvesikeln |
| WO2015058148A1 (en) * | 2013-10-17 | 2015-04-23 | Children's Hospital Los Angeles | Antibody dependent exosome therapy |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| KR102717969B1 (ko) | 2014-02-21 | 2024-10-15 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 글리코타겟팅 치료제 |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| TW201627318A (zh) * | 2014-10-22 | 2016-08-01 | 臺北醫學大學 | 膽固醇酯轉運蛋白抗原肽及其融合蛋白以及其組合物及應用 |
| US10702581B2 (en) | 2015-05-04 | 2020-07-07 | Ilias Biologics Inc. | Compositions containing protein loaded exosome and methods for preparing and delivering the same |
| KR20160130937A (ko) * | 2015-05-04 | 2016-11-15 | 한국과학기술원 | 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법 |
| US20180177727A1 (en) | 2015-06-10 | 2018-06-28 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
| US9840542B2 (en) | 2015-09-11 | 2017-12-12 | Nomadogen Biotechnologies Inc. | Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells |
| WO2017118764A1 (en) * | 2016-01-07 | 2017-07-13 | Thomas Brocker | Novel approaches for the in vivo and in vitro visualization of dying cells |
| WO2017127827A1 (en) | 2016-01-22 | 2017-07-27 | Tufts Medical Center | Compounds and methods for treating inflammation |
| US20190091307A1 (en) | 2016-03-03 | 2019-03-28 | Institut Gustave Roussy | Ptps-based vaccines against cancer |
| WO2017173367A2 (en) | 2016-03-31 | 2017-10-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extracellular vesicles, methods of making them, and methods of reducing liver uptake of extracellular vesicles |
| US20190112351A1 (en) * | 2016-04-04 | 2019-04-18 | National Institutes Of Biomedical Innovation, Health And Nutrition | Exosome-targeted dna vaccine |
| JP2019528674A (ja) * | 2016-09-30 | 2019-10-17 | セレックス ライフ サイエンシズ，インコーポレーテッド | タンパク質をロードしたエキソソームを含む組成物、並びにその調製及び送達のための方法 |
| US10487143B2 (en) * | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| CN108324735B (zh) * | 2017-01-20 | 2024-02-09 | 李莉 | 用于疾病治疗的胞外体制剂及其应用 |
| CN107185612B (zh) * | 2017-03-17 | 2020-12-01 | 庶安永龄(厦门)健康产业有限公司 | 一种应用于外泌体捕获的微流体芯片及其制备方法 |
| US11672849B2 (en) * | 2017-05-10 | 2023-06-13 | University Of Louisville Research Foundation, Inc. | Method of inhibiting lung or breast cancer growth with engineered embryonic stem-cell derived exosomes compositions |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| EP3661556A4 (de) * | 2017-07-29 | 2021-04-28 | University of Southern California | Synthetische extrazelluläre vesikel für neuartige therapien |
| WO2019028450A1 (en) * | 2017-08-04 | 2019-02-07 | Ohio State Innovation Foundation | PROCESS FOR THE PRODUCTION OF THERAPEUTIC EXOSOMES FROM NANOELECTROPORATION AND OTHER TRANSFECTION OF NON-ENDOCYTIC CELL |
| US11517530B2 (en) * | 2017-09-27 | 2022-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic agents specifically delivered by exosomes for cancer treatment |
| AU2018394238A1 (en) | 2017-12-28 | 2020-06-18 | Lonza Sales Ag | Exosomes for immuno-oncology and anti-inflammatory therapy |
| CN112218621A (zh) * | 2018-04-10 | 2021-01-12 | 西北大学 | 包含基于靶向亲和域的膜蛋白的胞外囊泡 |
| EA202092723A1 (ru) | 2018-05-09 | 2021-04-09 | Зе Юниверсити Оф Чикаго | Композиции и способы, касающиеся иммунной толерантности |
| CN113301914B (zh) * | 2018-10-25 | 2026-02-03 | 尼希尔有限公司 | 用于治疗和预防纤维化的组合物和方法 |
| WO2021045501A1 (ko) * | 2019-09-02 | 2021-03-11 | 경북대학교 산학협력단 | Il-2 표면 발현 세포외 소포체를 유효성분으로 포함하는 암 질환 예방 또는 치료용 조성물 |
| CN112824530A (zh) * | 2019-11-20 | 2021-05-21 | 中国科学院深圳先进技术研究院 | 一种hek293f悬浮细胞高效电转染方法 |
| WO2021151029A1 (en) * | 2020-01-22 | 2021-07-29 | Agex Therapeutics, Inc. | Therapeutic exosomes and method of producing them |
| EP4099984A4 (de) | 2020-02-05 | 2024-05-01 | Diadem Biotherapeutics Inc. | Künstliche synapsen |
| US20230288437A1 (en) * | 2020-03-30 | 2023-09-14 | Shinshu University | Quantification method for modified hdl, and analysis reagent for use in same method |
| US20250026802A1 (en) | 2021-12-06 | 2025-01-23 | Ciloa | Chimeric adiponectin polypeptides, extracellular vesicle comprising the same, and uses thereof |
| CN116082517B (zh) * | 2022-05-26 | 2025-08-22 | 成都地奥制药集团有限公司 | 融合蛋白及其用途 |
| CN116162597B (zh) * | 2022-12-12 | 2025-12-19 | 中国科学技术大学 | 装载有Wnt蛋白的工程化细胞外囊泡及其应用 |
| CN116676265B (zh) * | 2023-04-18 | 2024-05-24 | 河南中医药大学第一附属医院 | 一种酸敏融合肽靶向外泌体及其制备方法和应用 |
| CN116769717B (zh) * | 2023-04-18 | 2024-06-11 | 河南中医药大学第一附属医院 | 一种靶向外泌体及其制备方法和应用 |
| EP4537820A1 (de) | 2023-10-13 | 2025-04-16 | Institut Gustave-Roussy | Verbindung und kombinationen mit dieser verbindung zur verbesserung der immunreaktion |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455031A (en) | 1990-11-01 | 1995-10-03 | Cancer Research Fund Of Contra Costa | Polypeptide with 46 Kdalton HMFG differentiation antigen binding specificity, composition, kit and diagnostic method |
| US5972337A (en) * | 1990-11-01 | 1999-10-26 | Cancer Research Fund Of Contra Costa | 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein |
| IT1264516B1 (it) | 1993-05-31 | 1996-09-24 | Biotop Sas Di Rita Cassarin | Cellule dendritiche immortalizzate |
| US20030198642A1 (en) | 1995-08-03 | 2003-10-23 | Johannes J. Geuze | Cell derived antigen presenting vesicles |
| US5834015A (en) | 1996-09-11 | 1998-11-10 | Albany Medical College | Protein-lipid vesicles and autogenous vaccine comprising the same |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| FR2785543B1 (fr) * | 1998-11-05 | 2003-02-28 | Inst Nat Sante Rech Med | Exosomes modifies et utilisations |
| EP1004664A1 (de) | 1998-11-24 | 2000-05-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Zusammensetzungen und Verfahren unter Verwendung von Lactadherin oder Lactadherinderivaten |
| FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
| US20040241176A1 (en) | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
| US6410271B1 (en) | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Generation of highly diverse library of expression vectors via homologous recombination in yeast |
| WO2002056831A2 (en) | 2000-12-27 | 2002-07-25 | Dana-Farber Cancer Institute, Inc. | Immunogenic proteoliposomes, and uses thereof |
| ATE512982T1 (de) | 2001-08-17 | 2011-07-15 | Exothera L L C | Verfahren und zusammensetzung zum gezielten einbringen in exosome |
| JP2005528091A (ja) | 2002-03-14 | 2005-09-22 | アノシス・インコーポレーテッド | Ｔ細胞由来小胞の機能化、および免疫原性医薬組成物を製造するためのその使用 |
-
2002
- 2002-08-14 AT AT02767380T patent/ATE512982T1/de not_active IP Right Cessation
- 2002-08-14 IL IL16014202A patent/IL160142A0/xx unknown
- 2002-08-14 CN CN02816094A patent/CN100590131C/zh not_active Expired - Fee Related
- 2002-08-14 JP JP2003521831A patent/JP4662708B2/ja not_active Expired - Fee Related
- 2002-08-14 US US10/485,360 patent/US7704964B2/en not_active Expired - Fee Related
- 2002-08-14 AU AU2002331244A patent/AU2002331244B2/en not_active Ceased
- 2002-08-14 CA CA2454756A patent/CA2454756C/en not_active Expired - Fee Related
- 2002-08-14 EP EP02767380A patent/EP1417229B1/de not_active Expired - Lifetime
- 2002-08-14 WO PCT/EP2002/009108 patent/WO2003016522A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US7704964B2 (en) | 2010-04-27 |
| AU2002331244B2 (en) | 2007-02-15 |
| JP4662708B2 (ja) | 2011-03-30 |
| CN100590131C (zh) | 2010-02-17 |
| CA2454756A1 (en) | 2003-02-27 |
| JP2005503791A (ja) | 2005-02-10 |
| WO2003016522A3 (en) | 2003-08-28 |
| CN1543476A (zh) | 2004-11-03 |
| US20040197314A1 (en) | 2004-10-07 |
| IL160142A0 (en) | 2004-06-20 |
| WO2003016522A2 (en) | 2003-02-27 |
| EP1417229A2 (de) | 2004-05-12 |
| HK1062444A1 (en) | 2004-11-05 |
| CA2454756C (en) | 2014-02-18 |
| EP1417229B1 (de) | 2011-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE512982T1 (de) | Verfahren und zusammensetzung zum gezielten einbringen in exosome | |
| EP2141243A3 (de) | Proteingerüste für Antikörpermimetika und andere Bindungsproteine | |
| MY162624A (en) | Antibodies directed to her-3 and uses thereof | |
| MXPA02010670A (es) | Nuevas moleculas co-estimuladoras de celula dendritica. | |
| WO2006122825A3 (en) | Single domain vhh antibodies against von willebrand factor | |
| ATE184647T1 (de) | Embryonische stammzelle zur herstellung von chimäre und transgen-ongulaten | |
| ATE200679T1 (de) | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen | |
| MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
| ATE277198T1 (de) | Verfahren zur in vitro evolution von proteinfunktionen | |
| MXPA02008724A (es) | Receptores del gusto t1r y genes que codifican los mismos. | |
| ATE315652T1 (de) | Polypeptidzusammensetzungen von bacillus thuringiensis cryet70 die für diabrotica insekten toxisch sind, und methoden zur dessen verwendung | |
| PL364138A1 (en) | Proteins producing an altered immunogenic response and methods of making and using the same | |
| TR200001861T2 (tr) | Yeni G protein birleştirilmiş alıcı | |
| ATE271606T1 (de) | Die aktivierung von rezeptoren durch gas6 | |
| ATE112801T1 (de) | Menschliche lactoferrin-cdna-sequenz. | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| WO1995019435A3 (en) | T cell antigen receptor v region proteins and methods of preparation thereof | |
| EP1487966A4 (de) | Sekretion von proteinen mit mehreren disulfidbindungen in bakterien und verwendungen davon | |
| ATE135371T1 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
| DE69737651D1 (de) | Cortistatin: neuropeptide, zusammensetzungen und methoden | |
| ATE337336T1 (de) | Nukleinsäuren, die für stichodactylidae chromoproteine kodieren | |
| DE602004032345D1 (de) | Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen | |
| WO1999019470A3 (en) | Gfp-annexin fusion proteins | |
| EP1456239A4 (de) | Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne | |
| DE60320302D1 (de) | Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |